Elixxer

Elixxer Equity

The The Equity of Elixxer (ELXR.H.V) as of Oct 25, 2026 is -9.60 M CAD. In the previous year, The Equity was -5.58 M CAD — a change of 71.90% (lower).

Equity

-9.60 MCAD

YoY

71.90%

Last updated:

In 2023, Elixxer's equity was -9.60 M CAD, a 71.90% increase from the -5.58 M CAD equity in the previous year.

The Elixxer Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2016
7.55 M CAD
Jan 1, 2017
1.58 M CAD
Jan 1, 2018
17.67 M CAD
Jan 1, 2019
13.18 M CAD
Jan 1, 2020
4.76 M CAD
Jan 1, 2021
8.38 M CAD
Jan 1, 2022
-5.58 M CAD
Jan 1, 2023
-9.60 M CAD
The Elixxer Equity history
YEAREquityYoY
-9.60 MCAD+71.90%
-5.58 MCAD-166.64%
8.38 MCAD+76.12%
4.76 MCAD-63.89%
13.18 MCAD-25.43%
17.67 MCAD+1,021.23%
1.58 MCAD-79.12%
7.55 MCAD+69,817.59%
10,800.00CAD-97.57%
444,100.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Elixxer Stock analysis

What does Elixxer do? Elixxer Ltd. invests in cannabis-related businesses licensed for cultivation, production, and sale of cannabis and cannabis-derived products. The company focuses on medical cannabis and specialty pharmaceutical products, growing and producing medical-grade cannabis for global markets. Its brands include Viridi, Easyjoint, Freia, Little Green Pharma (LGP), and One Premium Cannabis, which are used for CBD cosmetics, natural wellness products, and pharmaceutical applications. Elixxer targets medical and wellness segments through its subsidiaries in Australia, Canada, Switzerland, Italy, and Jamaica, where it operates cultivation, extraction, and production facilities for legal cannabis products. The company generates revenue through its portfolio of cannabis investments, including nutraceutical, cosmetics, and pharmaceutical segments. Its subsidiaries LGC Finance Limited, LGC Capital EU OU, and LGC Capital Spain S.L. support its global operations, while its brands cater to consumers seeking CBD-based wellness solutions and medical cannabis products. Elixxer's focus on medical cannabis and pharmaceutical applications drives its market positioning in the global cannabis industry. Elixxer Ltd. primarily serves medical and specialty cannabis markets, with a strong emphasis on pharmaceutical-grade products. Its investments span cultivation, extraction, and production facilities across multiple countries, enabling it to supply global markets with medical cannabis and CBD-derived products. The company's brands are positioned within the wellness and pharmaceutical sectors, targeting consumers and healthcare providers interested in natural and medical cannabis solutions. Elixxer is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Elixxer's Equity

Elixxer's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Elixxer's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Elixxer's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Elixxer's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Elixxer’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Elixxer stock

The Equity of Elixxer is -9.60 M CAD in 2023.

The Equity of Elixxer changed from -5.58 M CAD to -9.60 M CAD, representing a 71.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Elixxer since 2006 – with annual values, charts, and detailed analysis.

The Equity's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Elixxer historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Elixxer

All Key Metrics — Elixxer